Jennell Palaia
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Lymphoma Diagnosis and Treatment, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer(2023)53 cited
- → First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data(2024)47 cited
- → First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.(2024)3 cited
- → Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data(2024)3 cited
- → Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data(2025)2 cited
- → Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC).(2024)2 cited
- → Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).(2023)2 cited
- → CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)(2023)1 cited
- → Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments(2025)1 cited
- → Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047(2025)1 cited